GO
| HSI1 | 25,818.93 | +44.79 | 92.52B |
| HSCEI1 | 8,915.12 | +1.29 | 34.27B |
| Back Zoom + Zoom - Block Traded | |
|
2025-12-24 10:16:22 The total sample drug sales in China's pharmaceutical industry declined by 3% YoY in October, a sharp drop from the 6.8% YoY growth in September, BofA Securities released a research report saying. HANSOH PHARMA (03692.HK) achieved the highest YoY incline among its peers in October, at 8.6%, the report noted. Most of HANSOH PHARMA's key products recorded double-digit MoM growth in October, except for PEG-loxenatide. Therefore, the broker kept rating at Buy, with a target price of $45. Several key products of HENGRUI PHARMA (01276.HK) faced pressure in October, the report stated. The total sample sales hiked by 2% YoY in October. Therefore, BofA Securities kept rating at Underperform, with a target price of RMB57.7 for HENGRUI PHARMA's A-shares. SINO BIOPHARM (01177.HK) showed mixed performance in its product mix in October, the report added. Based on sales performance, the broker lowered its sales forecasts for some products affected by VBP starting in 2026, and reduced its 2026/ 2027 revenue forecasts by 0.2%/ 0.4% each. Therefore, BofA Securities cut its target price from $9.4 to $8.3, and reiterated rating at Buy based on the massive licensing potential of its pipeline products. Moreover, as several key drug sales of CSPC PHARMA (01093.HK) remained sluggish in October, the broker kept rating at Underperform, with a target price of $7.2. ~ AASTOCKS Financial News Website: www.aastocks.com | |